Maddi Hebebrand, MC, Associate Editor

Neuroimmune modulation, including vagus nerve stimulation, is highlighted as a promising strategy for patients unresponsive to biologics.

Kilian Eyerich, MD, PhD, argues that classifying skin diseases by immune response patterns offers clearer therapeutic guidance than traditional morphology.

Michael Rosenblum’s team identified a previously underappreciated fibroblast subset that actively regulates inflammation, fibrosis, and microbial containment in the skin.

Therapeutic modulation of mitochondria offers a pathway to control multiple cytokine pathways simultaneously.

Chronic itching can reflect systemic disease, highlighting the importance of comprehensive assessment.

Robert Bissonnette, MD, presented tape-strip transcriptomics detecting meaningful steroid responses after just 1 day of therapy.

Kim explores the significance of inflammation in dermatology, revealing its connections to various diseases and the importance of focused research.

The study supports the hypothesis that targeting oxidative stress could complement phototherapy in restoring pigmentation in vitiligo.

Marc Serota, MD, notes that areas lacking hair follicles respond more slowly to therapy and benefit from long-term, low-risk use of topical ruxolitinib.

Nemolizumab shows significant efficacy in reducing pruritus and improving skin clearance in patients with prurigo nodularis, offering new therapeutic hope.

Experts discuss essential skin care strategies for sensitive skin, emphasizing evidence-based cleansing and moisturizing to restore the compromised skin barrier.

Lindsay Ackerman, MD, FAAD, shares practical insights on managing vitiligo with topical ruxolitinib, addressing patient expectations, safety, and evolving research gaps.

The topline data support advancing INF904 into larger, controlled trials as a potential convenient alternative to injectable biologics.

Experts discuss icotrokinra's potential to revolutionize psoriasis treatment with oral therapies, emphasizing efficacy, safety, and patient-centered care at EADV 2025.

Findings suggest immune dysregulation and chronic inflammation in atopic dermatitis may contribute to increased skin cancer susceptibility.

An AI-powered handheld spectroscopy device is showing promise in improving melanoma detection accuracy among primary care physicians, addressing critical gaps in early diagnosis and timely referral.

Clinical trials DELTA 1, 2, 3, and DELTA FORCE demonstrated significant improvements in CHE severity and patient-reported outcomes with delgocitinib.

A phase 2 extension trial found roflumilast foam safe and effective for up to 52 weeks in patients with moderate to severe seborrheic dermatitis.

Lindsay Ackerman, MD, explains the importance of transparency when prescribing medications with boxed warnings.

Castle Biosciences’ new test uses molecular signatures from lesional skin to guide systemic therapy decisions in moderate to severe AD.

From acne to psoriasis, nutrition influences disease severity, treatment response, and patient quality of life.

Phio Pharmaceuticals reveals promising results for PH-762, a novel siRNA therapy targeting skin cancer, showcasing effective tumor clearance and safety.

Advances in atopic dermatitis research could bring longer-lasting biologics and improved treatment adherence.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Christopher Bunick, MD, PhD, emphasizes how dermatologists can improve outcomes through vigilant skin exams and collaborative care with oncology teams.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Christopher Bunick, MD, PhD, urged clinicians to move beyond therapeutic inertia and transition patients to advanced systemic therapies.

The Phoenix-based dermatologist encourages innovative and patient-tailored strategies to optimize pigment restoration.

Updated FDA policies eliminate many comparative efficacy trials, reducing biosimilar development time and cost by relying more on analytical testing.